Factors that delay malaria diagnosis and treatment in the municipality of Riberalta in Bolivia;Factores que retardan el diagnóstico y el tratamiento de la malaria en el municipio de Riberalta en Bolivia

Biomedica

Volumn 32, Issue SUPPL.1, 2012, Pages 38-45

  Añez, Arletta ^a   Suárez, Marco Fidel ^a   Cuba, Jorge ^b  

^a Programa de Malaria   (Bolivia)

^b Programa de Malaria Riberalta   (Bolivia)

Author keywords

Bolivia; Malaria diagnosis; Plasmodium; Signs and symptoms; Therapy

Indexed keywords

EID: 84869740437     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v32i0.581     Document Type: Article

References (29)

1. World Health Organization. World Malaria Report 2009. Geneva: WHO; 2009. Fecha de consulta: 29 de marzo de 2011. Disponible en: http://www.who.int/malaria/world_ malaria_report_2009/en/index.html.
2. World Health Organization. Malaria case management: Operation manual. Geneva: WHO; 2009. p. 55-65.
3. White JN. The role of anti-malarial drugs in eliminating malaria. Malar J. 2008;7:S8.
4. Price R, Nosten F, Simpson JA, Luxemburger C, Phaipun L, ter Kuile F, et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg.1999;60:1019-23.
5. Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V. The puberty of P. falciparum. Malar J. 2004;14:3-24.
6. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of P. vivax malaria. Am J Trop Med Hyg. 2001;64:S97-106.
7. Mckenzie F, Jeffery G, Collins W. P. vivax blood-stage dynamics. J Parasitol. 2002;88:521-35.
8. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377-410.
9. Engwerda C, Belnoue E, Grüner AC, Rénia L. Experimental model of cerebral en malaria. Curr Top Microbiol Immunol. 2005;297:103-43.
10. Collins WE, Jeffery GM. Retrospective examination of mosquito infection on humans infected with P. falciparum. Am J Trop Med Hyg. 2003;68:366-71.
11. Drakeley C, Sutherland C, Bousema JT, Sauerwein RW, Targett GA. The epidemiology of P. falciparum gametocytes: Weapons of mass dispersion. Trends Parasitol. 2006;22:424-30.
12. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996;347:1654-8.
13. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, et al. Artesunate reduces but does not prevent post-treatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001;183:1254-9.
14. Hommel M. Towards a research agenda for global malaria elimination. Malar J. 2008;7(Suppl.1):S1.
15. Kokwaro G. Ongoing challenges in the management of malaria. Malar J. 2009;8(Suppl.1):S2.
16. Global Malaria Programme. Malaria elimination: A field manual for low and moderate endemic countries. Geneva: WHO; 2007.
17. Hacer Retroceder la Malaria y Socios. Guía de monitoreo y evaluación VIH-sida, tuberculosis y malaria. Second edition. Ginebra; 2003. Fecha de consulta: 29 de marzo de 2011. Disponible en: http://www.theglobalfund.org/ documents/me/M_E_Toolkit_es.pdf.
18. Organización Mundial de la Salud, Departamento Hacer Retroceder la Malaria. Malaria control today. Current WHO Recommendations. Working Document. Ginebra, 2005. p.65 Fecha de consulta: 29 de marzo de 2011. Disponible en: http://www.who.int/malaria/docs/MCT_workingpaper.pdf.
19. Roll Back Malaria Partnership. Guidelines for core population-based indicators 2009. RBM/WG/2009/TP.1. Geneva: WHO; 2009. Fecha de consulta: 29 de marzo de 2011. Disponible en: http://www.rollbackmalaria.org/ partnership/wg/wg_monitoring/docs/GuidelinesForCorePop ulationFINAL9-20_Malaria.pdf.
20. World Health Organization. The African Summit on Roll Back Malaria. WHO/CDS/RBM/2000.17. Geneva: WHO; 2000.
21. Bedoya GE, Bedoya SA. Enganche y servidumbre por deudas en Bolivia. Oficina Internacional del Trabajo. Ginebra: OIT; 2005. p. 21-43.
22. Organización Panamericana de la Salud. Informe de la situación del paludismo en las Américas, 2008. Washington, D.C.: OPS; 2010. p. 31-2 y 72-8.
23. World Health Organization. Treatment of uncomplicated P. falciparum malaria en: Guidelines for the treatment of malaria. NLM classification: WC 770. Second edition. Geneve: WHO; 2010. p. 13-32.
24. Price RN, Tjitra E, Guerra CA, Yeung S, White JN, Anstey MN. Vivax malaria neglected and not benign. Am J Trop Med Hyg. 2007;77:79-87.
25. Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J. 2011;10:212.
26. Gama BE, Lacerda MV, Daniel-Ribeiro CT, Ferreira-da-Cruz M de F. Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control. Mem Inst Oswaldo Cruz. 2011;106:159-66.
27. Giao PT, Vries PJ, Binh TQ, Nam NV, Kager PA. Early diagnosis and treatment of uncomplicated malaria and patterns of health seeking in Vietnam. Trop Med Int Health. 2005;10:919-25.
28. Organización Panamericana de la Salud. Plan estratégico regional contra la malaria en las Américas 2006-2010. Washington, D.C.: OPS; 2006. p. 27-9.
29. Parks W, Lloyd L. Planificación de la movilización y comunicación social para la prevención y el control del dengue, guía paso a paso. Ginebra: OMS; 2004. p. 5-11.